Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1891
No trial phase data available
No trial data available
No trial data available
No approval data available
- A six-week randomized controlled trial found that daily consumption of raw tomatoes and tomato sauce led to a greater reduction in hepatic steatosis measured by CAP compared to a tomato-free diet in adults with MASLD. - The median CAP decline was 35 dB/m in the tomato intervention group versus 18 dB/m in controls, with an adjusted difference of −26.63 dB/m (p = 0.003). - No significant changes were observed in body weight, BMI, liver stiffness, lipid profiles, or liver enzymes between groups after the intervention period. - Experts caution that the study's exclusion of participants with BMI over 30 and short duration limit generalizability to broader MASLD patient populations.
- Bright Minds Biosciences (NASDAQ: DRUG) will present at the Cantor Global Healthcare Conference on September 9, 2026, and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. - The company is developing highly selective 5-HT2 agonists for drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system disorders. - Bright Minds' pipeline targets 5-HT2C, 5-HT2A, and combined 5-HT2C/A receptors, with additional programs in chronic pain and impulse control disorders such as binge eating. - The company collaborates with the National Institutes of Health and the University of Texas Medical Branch to advance its development programs.
- An experimental mRNA vaccine developed by researchers at the Wuhan Institute of Virology demonstrated complete protection against Zaire and Sudan Ebola viruses and strong protection against Bundibugyo virus in rodent studies. - The vaccine combines mRNA encoding glycoproteins from all three virus strains plus shared nucleoproteins within a single lipid nanoparticle, potentially overcoming limitations of current single-strain vaccines. - While promising, the vaccine requires extensive additional testing in non-human primates and humans before potential clinical use, with experts noting the complex regulatory pathway for multivalent vaccines. - The development comes amid a current Bundibugyo virus outbreak affecting over 600 people in the Democratic Republic of the Congo and Uganda, declared a public health emergency by the WHO.
- Circurna and GATC Health announced a strategic partnership to apply advanced AI technology for optimizing circular RNA therapeutics development. - The collaboration will leverage GATC's AI platform to enhance lipid nanoparticle designs, targeting ligands, and payload candidates for Circurna's ciRNA platform. - Circular RNA offers enhanced stability and protein expression compared to traditional mRNA, positioning it as a next-generation therapeutic modality. - GATC Health will receive cash, equity compensation, and milestone-based payments as part of the agreement terms.
